Patents by Inventor Laurie A. Vander Veen

Laurie A. Vander Veen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protease Inhibitors Having Enhanced Features
    Publication number: 20110195940
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.
    Type: Application
    Filed: September 17, 2009
    Publication date: August 11, 2011
    Applicant: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Laurie A. Vander Veen, Timothy A. Riley
  • Oligomer-Protease Inhibitor Conjugates
    Publication number: 20110195912
    Abstract: Provided are small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water soluble oligomer.
    Type: Application
    Filed: September 17, 2009
    Publication date: August 11, 2011
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Laurie A. Vander Veen
  • Oligomer-Nucleoside Phosphate Conjugates
    Publication number: 20100286084
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Application
    Filed: September 18, 2008
    Publication date: November 11, 2010
    Applicant: Nektar Therapeutics
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Timothy A. Riley, Laurie A. Vander Veen, Aaron S. Hammons